DBV Technologies (NASDAQ:DBVT) outlined its late-stage plans for VIASKIN Peanut and its broader epicutaneous immunotherapy platform during a presentation at the Citizens Life Sciences Conference, with ...
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the ...
Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...
Châtillon, France, March 4, 2026DBV Technologies to Participate in Upcoming March Investor ConferencesDBV Technologies (Euronext: DBV – ISIN: ...
On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
DBV Technologies’ peanut allergy patch missed the mark—by a whisker—in a phase 3 trial but is still at least 50:50 for FDA approval, say analysts at Jefferies. Top-line data from the PEPITES study ...
Shares in DBV Technologies have shot up after it presented positive clinical trial results with an immunotherapy for peanut allergy that was rejected by the FDA several years ago. The Paris, ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...
In 2020, the FDA refused to approve DBV Technologies lead candidate, the Viaskin Peanut patch, citing adhesion issues. DBV enlarged the patch and had intended to try again without running a new phase ...
DBV announced that the FDA lifted a partial clinical hold on its phase 3 study of DBV712. The product is a patch intended for use in kids with peanut allergies. The FDA placed DBV Technologies' phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results